Castle Biosciences Inc’s filing revealed that its Officer Derek Maetzold acquired Company’s shares for reported $0.7 million on Mar 07 ’25. In the deal valued at $20.21 per share,34,821 shares were bought.
Then, Derek Maetzold bought 5,687 shares, generating $126,422 in total proceeds.
Before that, Stokes Frank sold 8,046 shares. Castle Biosciences Inc shares valued at $214,828 were divested by the Chief Financial Officer at a price of $26.70 per share. As a result of the transaction, Stokes Frank now holds 35,319 shares, worth roughly $0.67 million.
Guggenheim initiated its Castle Biosciences Inc [CSTL] rating to a Buy in a research note published on December 14, 2023; the price target was $25. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early January with a ‘”a Sector outperform”‘ rating. Stephens began covering CSTL with “an Overweight” recommendation on January 07, 2022. Lake Street started covering the stock on April 30, 2021. It rated CSTL as “a Buy”.
Price Performance Review of CSTL
On Monday, Castle Biosciences Inc [NASDAQ:CSTL] saw its stock fall -6.33% to $18.93. Over the last five days, the stock has lost -11.00%. Castle Biosciences Inc shares have fallen nearly -28.97% since the year began. Nevertheless, the stocks have fallen -11.79% over the past one year. While a 52-week high of $35.84 was reached on 01/08/25, a 52-week low of $16.97 was recorded on 03/10/25. SMA at 50 days reached $26.39, while 200 days put it at $26.91.
Levels Of Support And Resistance For CSTL Stock
The 24-hour chart illustrates a support level at 18.42, which if violated will result in even more drops to 17.90. On the upside, there is a resistance level at 19.73. A further resistance level may holdings at 20.52. The Relative Strength Index (RSI) on the 14-day chart is 22.43, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.45, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.41%. Stochastics %K at 4.63% indicates the stock is a buying.
The most recent change occurred on November 10, 2020 when KeyBanc Capital Markets began covering the stock and recommended ‘”an Overweight”‘ rating along with a $70 price target.
